Serum transforming growth factor-β1 level reflects disease status in patients with esophageal carcinoma after radiotherapy

World Journal of Gastroenterology

Volumn 13, Issue 39, 2007, Pages 5267-5272

  Sun, Su Ping ^a,d   Jin, Ye Ning ^b   Yang, Hong Peng ^a   Wei, Yi ^c   Dong, Zhao ^c  

^a JIANGSU UNIVERSITY   (China)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Esophageal carcinoma; Prognosis; Radiotherapy; TGF 1

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SURVIVAL RATE; SURVIVAL TIME;

EID: 34948903346     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i39.5267     Document Type: Article

References (31)

1. Yamada S, Takai Y, Nemoto K, Ogawa Y, Kakuto Y, Hoshi A, Sakamoto K. Low-dose rate telecobalt therapy as a boost against esophageal carcinomas. Cancer 1992; 69:1099-1103
2. Smalley SR, Gunderson LL, Reddy EK, Williamson S. Radiotherapy alone in esophageal carcinoma: current management and future directions of adjuvant, curative and palliative approaches. Semin Oncol 1994; 21:467-473
3. Wang Y, Shi XH, He SQ, Yao WQ, Wang Y, Guo XM, Wu GD, Zhu LX, Liu TF. Comparison between continuous accelerated hyperfractionated and late-course accelerated hyperfractionated radiotherapy for esophageal carcinoma. Int J Radiat Oncol Biol Phys 2002; 54:131-136
4. Gao XS, Qiao XY, Yang XR, Asaumi J, Zhou ZG, Wang YD, Zhou DA, Wan J, Kuroda M, Kishi K, Kawasaki S, Hiraki Y. Late course accelerated hyperfractionation radiotherapy concomitant with cisplatin in patients with esophageal carcinoma. Oncol Rep 2002; 9:767-772
5. Zhao KL, Wang Y, Shi XH. Late course accelerated hyperfractionated radiotherapy for clinical T1-2 esophageal carcinoma. World J Gastroenterol 2003; 9:1374-1376
6. Shi XH, Yao W, Liu T. Late course accelerated fractionation in radiotherapy of esophageal carcinoma. Radiother Oncol 1999; 51:21-26
7. Zhao KL, Shi XH, Jiang GL, Yao WQ, Guo XM, Wu GD, Zhu LX. Late course accelerated hyperfractionated radiotherapy plus concurrent chemotherapy for squamous cell carcinoma of the esophagus: a phase III randomized study. Int J Radiat Oncol Biol Phys 2005; 62:1014-1020
8. Okunieff P, Cornelison T, Mester M, Liu W, Ding I, Chen Y, Zhang H, Williams JP, Finkelstein J. Mechanism and modification of gastrointestinal soft tissue response to radiation: role of growth factors. Int J Radiat Oncol Biol Phys 2005; 62:273-278
9. Feltl D, Zavadova E, Pala M, Hozak P. Post-treatment plasma transforming growth factor beta 1 (TGF-beta1) level predicts for late morbidity in patients with advanced head and neck cancer. Neoplasma 2005; 52:393-397
10. Anscher MS, Kong FM, Marks LB, Bentel GC, Jirtle RL. Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis. Int J Radiat Oncol Biol Phys 1997; 37:253-258
11. Evans ES, Kocak Z, Zhou SM, Kahn DA, Huang H, Hollis DR, Light KL, Anscher MS,. Marks LB. Does transforming growth factor-beta1 predict for radiation-induced pneumonitis in patients treated for lung cancer? Cytokine 2006; 3-4:186-192
12. Anscher MS, Marks LB, Shafman TD, Clough R, Huang H, Tisch A, Munley M, Herndon JE, Garst J, Crawford J, Jirtle RL. Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy. Int J Radiat Oncol Biol Phys 2003; 56:988-995
13. De Jaeger K, Seppenwoolde Y, Kampinga HH, Boersma LJ, Belderbos JS, Lebesque JV. Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004; 58:1378-1387
14. Pasche B. Role of transforming growth factor beta in cancer. J Cell Physiol 2001; 186:153-168
15. Tsushima H, Ito N, Tamura S, Matsuda Y, Inada M, Yabuuchi I, Imai Y, Nagashima R, Misawa H, Takeda H, Matsuzawa Y, Kawata S. Circulating transforming growth factor beta 1 as a predictor of liver metastasis after resection in colorectal cancer. Clin Cancer Res 2001; 7:1258-1262
16. Wu HS, Li YF, Chou CI, Yuan CC, Hung MW, Tsai LC. The concentration of serum transforming growth factor beta-1 (TGF-beta1) is decreased in cervical carcinoma patients. Cancer Invest 2002; 20:55-59
17. Bierie B, Moses HL. TGF-beta and cancer. Cytokine Growth Factor Rev 2006; 17:29-40
18. Fukai Y, Fukuchi M, Masuda N, Osawa H, Kato H, Nakajima T, Kuwano H. Reduced expression of transforming growth factor-beta receptors is an unfavorable prognostic factor in human esophageal squamous cell carcinoma. Int J Cancer 2003; 104:161-166
19. Fukuchi M, Miyazaki T, Fukai Y, Nakajima M, Sohda M, Masuda N, Manda R, Tsukada K, Kato H, Kuwano H. Plasma level of transforming growth factor beta1 measured from the azygos vein predicts prognosis in patients with esophageal cancer. Clin Cancer Res 2004; 10:2738-2741
20. Anscher MS, Marks LB, Shafman TD, Clough R, Huang H, Tisch A, Munley M, Herndon JE 2nd, Garst J, Crawford J, Jirtle RL. Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation. J Clin Oncol 2001; 19:3758-3765
21. Leonard GD, McCaffrey JA, Maher M. Optimal therapy for oesophageal cancer. Cancer Treat Rev 2003; 29:275-282
22. Song BC, Chung YH, Kim JA, Choi WB, Suh DD, Pyo SI, Shin JW, Lee HC, Lee YS, Suh DJ. Transforming growth factor-beta1 as a useful serologic marker of small hepatocellular carcinoma. Cancer 2002; 94:175-180
23. Anscher MS, Kong FM, Andrews K, Clough R, Marks LB, Bentel G, Jirtle RL. Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 1998; 41:1029-1035
24. Kong FM, Washington MK, Jirtle RL, Anscher MS. Plasma transforming growth factor-beta 1 reflects disease status in patients with lung cancer after radiotherapy: a possible tumor marker. Lung Cancer 1996; 16:47-59
25. Ivanovic V, Todorovic-Rakovic N, Demajo M, Neskovic-Konstantinovic Z, Subota V, Ivanisevic-Milovanovic O, Nikolic-Vukosavljevic D. Elevated plasma levels of transforming growth factor-beta 1 (TGF-beta 1) in patients with advanced breast cancer: association with disease progression. Eur J Cancer 2003; 39:454-461
26. Dickson J, Davidson SE, Hunter RD, West CM. Pretreatment plasma TGF beta 1 levels are prognostic for survival but not morbidity following radiation therapy of carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2000; 48:991-995
27. Yang YC, Wang KL, Su TH, Liao HF, Wu MH, Chen TC, Huang MC, Chen YJ. Concurrent cisplatin-based chemoradiation for cervical carcinoma: tumor response, toxicity, and serum cytokine profiles. Cancer Invest 2006; 24:390-395
28. Maehara Y, Kakeji Y, Kabashima A, Emi Y, Watanabe A, Akazawa K, Baba H, Kohnoe S, Sugimachi K. Role of transforming growth factor-beta 1 in invasion and metastasis in gastric carcinoma. J Clin Oncol 1999; 17:607-614
29. Kong FM, Anscher MS, Murase T, Abbott BD, Iglehart JD, Jirtle RL. Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg 1995; 222:155-162
30. Shariat SF, Shalev M, Menesses-Diaz A, Kim IY, Kattan MW, Wheeler TM, Slawin KM. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 2001; 19:2856-2864
31. Robson H, Anderson E, James RD, Schofield PF. Transforming growth factor beta 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients. Br J Cancer 1996; 74:753-758